{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:18:38Z","timestamp":1794449918557,"version":"4.9.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>CXCL13 regulates the homing of lymphocytes. It is highly expressed in kidney and serum of SLE patients, and correlates with disease activity, but its value in LN is unclear. This study was to investigate the expression and diagnostic value of CXCL13 and its regulated CXCR5<jats:sup>+<\/jats:sup> T cells in LN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In mice, the association of serum CXCL13 levels with renal function was analyzed. And CXCR5<jats:sup>+<\/jats:sup> T cell was detected by H&amp;amp;E staining and immunofluorescence in kidney, and by flow cytometry in spleen. In clinical studies, the association of CXCL13 and CXCR5<jats:sup>+<\/jats:sup> T cells with disease activity was verified, and their diagnostic efficacy was assessed by ROC curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CXCL13 was elevated in both mouse and patients, and was positively correlated with disease severity. Serum CXCL13 had an AUC of 0.9287 in the diagnosis of SLE and 0.6244 in differential diagnosis of LN. And in MRL\/lpr mice, CXCL13 was involved in the development of nephritis by promoting the recruitment of CXCR5<jats:sup>+<\/jats:sup> T cells to the kidney. In the peripheral blood of LN patients, CXCR5<jats:sup>+<\/jats:sup> T cells were significantly reduced. Combined detection of CXCR5<jats:sup>+<\/jats:sup> T cell subsets resulted in an AUC of 0.9672 for the diagnosis of SLE and 0.7867 for the differential diagnosis of LN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Serum CXCL13 has high accuracy in the diagnosis of SLE, and circulating CXCR5<jats:sup>+<\/jats:sup> T cells may serve as a novel biomarker for the diagnosis of SLE and LN, which might complement the poor performance of serum CXCL13 in the diagnostic efficacy of LN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1657350","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:24:41Z","timestamp":1760419481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The utility of CXCL13 and circulating CXCR5+ T cell detection in the diagnosis of systemic lupus erythematosus associated nephritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080912","article-title":"The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort","volume":"36","author":"Peschken","year":"2009","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006","volume":"63","author":"Costenbader","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.004","article-title":"Current management of lupus nephritis","volume":"27","author":"Houssiau","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41581-021-00481-9","article-title":"Immune cell behaviour and dynamics in the kidney - insights from in vivo imaging","volume":"18","author":"Kitching","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/art.24136","article-title":"CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients","volume":"60","author":"Enghard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319826703","article-title":"Early-stage predictors for treatment responses in patients with active lupus nephritis","volume":"28","author":"Liu","year":"2019","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.09.027","article-title":"Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis","volume":"95","author":"Wilson","year":"2019","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.031","article-title":"CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection","volume":"72","author":"Li","year":"2020","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011557","article-title":"The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13","volume":"138","author":"Zanetti","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult Scler"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997862","article-title":"CXCL13 is elevated in inflammatory bowel disease in mice and humans and is implicated in disease pathogenesis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00707-x","article-title":"The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity","volume":"21","author":"Zeng","year":"2021","journal-title":"Clin Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3899\/jrheum.090450","article-title":"Serum BLC\/CXCL13 concentrations and renal expression of CXCL13\/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis","volume":"37","author":"Lee","year":"2010","journal-title":"J Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2015.09.001","article-title":"CXCL13 blockade attenuates lupus nephritis of MRL\/lpr mice","volume":"117","author":"Wu","year":"2015","journal-title":"Acta Histochem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763065","article-title":"CXCL13 neutralization attenuates neuropsychiatric manifestations in lupus-prone mice","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20572","article-title":"Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI)","author":"Romero-Diaz","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B21","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.22172","article-title":"IK cytokine ameliorates the progression of lupus nephritis in MRL\/lpr mice","volume":"54","author":"Muraoka","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/35018581","article-title":"A chemokine-driven positive feedback loop organizes lymphoid follicles","volume":"406","author":"Ansel","year":"2000","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204777","article-title":"Tertiary lymphoid structures as local perpetuators of organ-specific immune injury: implication for lupus nephritis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp343","article-title":"B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE)","volume":"24","author":"Schiffer","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03530509","article-title":"Biomarkers for lupus nephritis: the quest continues","volume":"4","author":"Rovin","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111005","article-title":"The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1938","article-title":"Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis","volume":"180","author":"Schiffer","year":"2008","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000008675","article-title":"The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: A STROBE-compliant article","volume":"96","author":"Fang","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320981396","article-title":"Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis","volume":"6","author":"DiSano","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.06.048","article-title":"CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis","volume":"380","author":"Iwanowski","year":"2017","journal-title":"J Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726592","article-title":"Defining active progressive multiple sclerosis","volume":"23","author":"Sellebjerg","year":"2017","journal-title":"Mult Scler"},{"key":"B33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12035-022-03060-6","article-title":"CSF CXCL13 and chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis","volume":"60","author":"Lucchini","year":"2023","journal-title":"Mol Neurobiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512463482","article-title":"Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13","volume":"19","author":"Lind\u00e9n","year":"2013","journal-title":"Mult Scler"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010425","article-title":"CXCL13 in cerebrospinal fluid: clinical value in a large cross-sectional study","volume":"25","author":"Erhart","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7676","article-title":"CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis","volume":"176","author":"Bagaeva","year":"2006","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12987-021-00272-1","article-title":"The CXCL13\/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF","volume":"18","author":"Harrer","year":"2021","journal-title":"Fluids Barriers CNS"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1657350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:24:42Z","timestamp":1760419482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1657350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1657350"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1657350","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1657350.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1657350"}}